GDTC — CytoMed Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $11.83m
- $10.80m
- SG$0.32m
Annual balance sheet for CytoMed Therapeutics, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS/A | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 2.51 | 1.58 | 9 | 4.97 | 2.1 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.005 | 0.058 | 0.205 | 0.121 | 0.132 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3.28 | 2.49 | 10.1 | 6 | 3.66 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.5 | 2.47 | 2.06 | 3.25 | 3.69 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 6.08 | 5.23 | 12.4 | 10.1 | 7.98 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.94 | 4.17 | 0.717 | 0.607 | 0.709 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Liabilities | 3.49 | 4.64 | 1.12 | 1.1 | 1.44 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 2.59 | 0.587 | 11.2 | 8.97 | 6.54 |
| Total Liabilities & Shareholders' Equity | 6.08 | 5.23 | 12.4 | 10.1 | 7.98 |
| Total Common Shares Outstanding |